BioInvent International AB (publ) (STO:BINV)

Market Cap	1.59B -34.8%
Revenue (ttm)	217.86M +258.3%
Net Income	-335.45M
EPS	-5.10
Shares Out	65.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,139
Open	25.15
Previous Close	24.80
Day's Range	23.75 - 25.45
52-Week Range	19.22 - 41.60
Beta	0.00
Analysts	Buy
Price Target	95.00 (+292.56%)
Earnings Date	Aug 27, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin’s lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 112
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for BINV stock is "Buy." The 12-month stock price target is kr 95.00, which is an increase of 292.56% from the latest price.

Price Target

kr 95.00

(292.56% upside)

Analyst Consensus: Buy